Carregant...
SUN-415 Panhypopituitarism: A Wake-Up Call in Patients Taking Anti-CTLA-4 Treatment
Background: Novel immune checkpoint proteins inhibitors, such cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) like ipilimumab could produce hypophysitis as a side effect with a prevalence between 0 to 10%. There are no guidelines in how to monitor patients receiving similar agents. We present a case...
Guardat en:
| Publicat a: | J Endocr Soc |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Endocrine Society
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553367/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-415 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|